NUCRYST Pharmaceuticals Corp. (NASD: NCST), a developer and manufacturer of medical products that fight infection and inflammation and the Advanced Wound Management division of Smith & Nephew, PLC, recently announced that Health Canada granted marketing approval for Acticoat™ Flex barrier dressing for wounds that require up to seven days of sustained antimicrobial activity.
Acticoat™ Flex simplifies the dressing of wounds with its unique elastic design that easily contours to surfaces, including difficult-to-protect regions, such as knee or elbow joints. Acticoat™ Flex is a new barrier dressing product that is coated with the company’s patented SILCRYST™ nanocrystalline silver technology. Acticoat dressings are now sold by Smith & Nephew in over 30 countries and are used extensively for serious wounds and burns.
Thomas E. Gardner, chairman and chief executive officer of NUCRYST Pharmaceuticals recently commented, “We are pleased that Health Canada has approved Acticoat™ Flex. This regulatory approval and the proposed launch by Smith & Nephew of Acticoat™ Flex is the latest result of the successful partnership between NUCRYST and Smith & Nephew to provide advanced antimicrobial protection to acute trauma and burn patients, as well as to patients with chronic wounds.”
Let us hear your thoughts below: